海南海藥(000566.SZ):半年度預虧1.2億元-1.6億元
格隆匯7月14日丨海南海藥(000566.SZ)公佈2025年半年度業績預吿,1-6月公司實現歸屬於上市公司股東的淨利潤虧損1.2億元-1.6億元,扣除非經常性損益後的淨利潤虧損1.4億元-1.7億元,基本每股收益虧損0.0925元/股-0.1233元/股。
2025年1月-6月,公司虧損額較上年同期有所下降。主要原因如下:
1.銷售費用同比下降。本報吿期銷售費用預計金額約0.86億元,較上年同期減少約0.60億元.主要系本報吿期公司推進降本控費、提質增效,同時,隨着行業政策的推行與實施,市場開發費減少所致。
2.投資收益同比上升。本報吿期投資收益預計金額約-0.05億元,較上年同期增加約0.46億元。主要系:(1)上年同期確認債務重組損失0.39億元,本期無此發生;(2)本報吿期交易性金融資產持有期間投資收益較上年同期增加所致。(此項為非經常性損益)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.